Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Arvinas, Inc.
Arvinas, Inc. News
Jun 13, 2025 - globenewswire.com
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
Jun 7, 2025 - prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Jun 6, 2025 - globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Arvinas, Inc. - ARVN
Jun 6, 2025 - globenewswire.com
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
Arvinas, Inc. Quantitative Score
About Arvinas, Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Arvinas, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Arvinas, Inc. Financials
Table Compare
Compare ARVN metrics with: | |||
|---|---|---|---|
Earnings & Growth | ARVN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ARVN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ARVN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ARVN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Arvinas, Inc. Income
Arvinas, Inc. Balance Sheet
Arvinas, Inc. Cash Flow
Arvinas, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Arvinas, Inc. Executives
| Name | Role |
|---|---|
| Dr. John G. Houston Ph.D. | Chairperson, Chief Executive Officer & President |
| Dr. Noah Berkowitz M.D., Ph.D. | Chief Medical Officer |
| Dr. Randy Teel Ph.D. | Chief Business Officer |
| Ms. Angela M. Cacace Ph.D. | Chief Scientific Officer |
| Mr. Andrew R. Saik | Chief Financial Officer & Treasurer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. John G. Houston Ph.D. | Chairperson, Chief Executive Officer & President | 1960 | 1.12M | |
| Dr. Noah Berkowitz M.D., Ph.D. | Chief Medical Officer | 1964 | 747.02K | |
| Dr. Randy Teel Ph.D. | Chief Business Officer | 1980 | 711.1K | |
| Ms. Angela M. Cacace Ph.D. | Chief Scientific Officer | Female | 1968 | 696.15K |
| Mr. Andrew R. Saik | Chief Financial Officer & Treasurer | Male | 1969 | 657.19K |
Arvinas, Inc. Insider Trades
| Date | 9 May |
| Name | Loomis David K |
| Role | Chief Accounting Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 11825 |
| Date | 9 May |
| Name | Loomis David K |
| Role | Chief Accounting Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 18100 |
| Date | 9 May |
| Name | Saik Andrew |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 59600 |
| Date | 9 May |
| Name | Saik Andrew |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 91000 |
| Date | 9 May |
| Name | Cacace Angela M |
| Role | Chief Scientific Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 59600 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 9 May | Loomis David K | Chief Accounting Officer | Acquired | A-Award | 11825 |
| 9 May | Loomis David K | Chief Accounting Officer | Acquired | A-Award | 18100 |
| 9 May | Saik Andrew | Chief Financial Officer | Acquired | A-Award | 59600 |
| 9 May | Saik Andrew | Chief Financial Officer | Acquired | A-Award | 91000 |
| 9 May | Cacace Angela M | Chief Scientific Officer | Acquired | A-Award | 59600 |